Breaking Finance News

JP Morgan Cazenove retained Vectura Group PLC (LON:VEC) to Overweight in a statement released today.

Yesterday Vectura Group PLC (LON:VEC) traded 3.27% higher at 97.00GBX. The company’s 50-day moving average is 102.39GBX and its 200-day moving average is 114.70GBX. The last closing price is down -11.77% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time. 1,114,830 shares of the stock were exchanged, down from an average trading volume of 1,633,170

JP Morgan Cazenove has retained Vectura Group PLC (LON:VEC) to Overweight in a report released on 11/15/2017.

Previously on 11/14/2017, Peel Hunt reported on Vectura Group PLC (LON:VEC) held steady the target price at 160.00GBX. At the time, this indicated a possible upside of 0.77%.

See Chart Below

Vectura Group PLC (LON:VEC)

Vectura Group PLC has a 52 week low of 88.90GBX and a 52 week high of 166.97GBX The company’s market cap is currently 0 GBX.

In addition to JP Morgan Cazenove reporting its target price, a total of 6 brokers have issued a report on the stock. The consensus target price is 215.67GBX with 4 brokers rating the stock a strong buy, 2 brokers rating the stock a buy, 1 broker rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Vectura Group PLC (LON:VEC)

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *